SCHEMBL16200816

SCHEMBL16200816

CC(C)(C)OC(=O)NC1CCN(Cc2ccc(=O)n(Cc3cccnc3)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.52
NPY5R Q15761 4/20 0.49
SLC6A5 Q9Y345 1/20 0.49
CHRM2 P08172 1/20 0.49
CHRM1 P11229 1/20 0.49
CHRM3 P20309 1/20 0.49
DRD4 P21917 1/20 0.49
CXCR4 P61073 1/20 0.47
AKT1 P31749 1/20 0.46
BRD4 O60885 1/20 0.44
KCNA3 P22001 1/20 0.44
PARP1 P09874 1/20 0.43
PARP2 Q9UGN5 1/20 0.43
KDM4E B2RXH2 1/20 0.43
KCNH2 Q12809 1/20 0.43
MCHR1 Q99705 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15033052 0.86 SIGMAR1 (0.60) SIGMAR1NPY5RSLC6A5CHRM2CHRM1
SCHEMBL6968971 0.85 NPY5R (0.57) SIGMAR1NPY5RSLC6A5CHRM2CHRM1
SCHEMBL16200832 0.83 SIGMAR1 (0.52) SIGMAR1NPY5RSLC6A5CHRM2CHRM1
SCHEMBL18569901 0.82 SIGMAR1 (0.51) SIGMAR1SLC6A5CHRM2CHRM1CHRM3
SCHEMBL16200828 0.80 KCNA3 (0.47) SIGMAR1AKT1KCNA3PARP1PARP2
SCHEMBL648348 0.78 SIGMAR1 (0.60) SIGMAR1CHRM2CHRM1CHRM3AKT1
SCHEMBL16194574 0.78 SLC6A5 (0.47) SIGMAR1NPY5RSLC6A5CHRM2CHRM1
SCHEMBL915402 0.78 KMT2A (0.65) SIGMAR1DRD4KCNA3MCHR1KMT2A
SCHEMBL23013177 0.77 CACNA1I (0.61) SIGMAR1NPY5RCXCR4KDM4EKMT2A
SCHEMBL29508424 0.77 CACNA1I (0.61) SIGMAR1NPY5RCXCR4KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2991981-B1 DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INT (DE) 2017-03-01 EP disclosed
US-9018215-B2 Heteroaromatic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-28 US disclosed
US-9018215-B2 Heteroaromatic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-28 US disclosed
WO-2014177469-A1 DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH,M (DE) 2014-11-06 WO disclosed
US-20140323447-A1 HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-30 US disclosed
US-20140323447-A1 HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323447-A1 HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF SCNN1B, SCNN1A, SCNN1G SIGMAR1 1090/4885NPY5R 2157/4885SLC6A5 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.